Medicure's MC-4232 reduces C-Reactive Protein in phase 2 Matched study

By Lisa Kerner

Charlotte, N.C., June 12 - Medicure Inc. said study results from its phase 2 Matched study demonstrated that MC-4232, a combination of MC-1 and the ACE inhibitor lisinopril (300 mg/20 mg), had a statistically significant 1.03 mg/L reduction in C-Reactive Protein (CRP) compared to baseline.

The 16-week randomized, double-blind Matched (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics) study compared 100 mg, 300 mg or 1,000 mg of MC-1 alone and in combination with 20 mg of lisinopril.

A total of 120 patients with coexisting type 2 diabetes and hypertension from 12 sites across Canada participated in the study, which also demonstrated a statistically significant reduction in primary blood pressure and metabolic endpoints.

CRP, a biomarker of inflammation, is predictive of cardiovascular risk.

"The reduction in CRP adds to the growing evidence of MC-4232's unique cardiovascular and metabolic benefits, and specifically MC-1's novel cardioprotective properties," president and chief executive officer Albert D. Friesen said in a company news release.

The study results were presented at the American Diabetes Association Annual Scientific Session in Washington, D.C.

Medicure is a cardiovascular drug discovery and development company located in Winnipeg, Man.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.